A population-based study of chronic neutrophilic leukemia in the United States

Gordon Ruan, Caleb J. Smith, Courtney N. Day, William S. Harmsen, Darci Zblewski, Hassan B. Alkhateeb, Kebede H. Begna, Aref Al‐Kali, Mark R. Litzow, William J. Hogan,

Blood Cancer Journal · 2020 · 16 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

Chronic neutrophilic leukemia (CNL) is a rare and aggressive BCR-ABL1 (Philadelphia chromosome) negative myeloproliferative neoplasm that carries a poor prognosis. It is defined by persistent mature neutrophilic leukocytosis, bone marrow granulocytic hyperplasia, and hepatosplenomegaly 1 . Despite the 2013 seminal discovery of the oncogenic driver mutations in colony-stimulating factor 3 receptor ( CSF3R ) in CNL 2 , no standard of care exists. Chemotherapy is not able to provide durable responses, the literature on allogeneic stem cell transplantation (ASCT) is scarce, and targeted therapies such as JAK-2 inhibitors and dasatinib are still being studied for efficacy and safety 1 , 3 , 4 . There is a paucity of population-based data on CNL and contemporary clinical data are limited to institutional case series. In this study, we combined the Surveillance, Epidemiology, and End Results (SEER) program and the National Cancer Database (NCDB) to study population-based outcomes for patients with CNL.

References

3